Literature DB >> 9192113

Enantiomeric determination of the phenylmorpholinol metabolite of bupropion in human plasma using coupled achiral-chiral liquid chromatography.

R F Suckow1, M F Zhang, T B Cooper.   

Abstract

A coupled achiral-chiral stationary phase liquid chromatographic technique was developed to separate and quantitate the enantiomers of the phenylmorpholinol metabolite (2) of the antidepressant bupropion (1) in human plasma. At the retention time of 2, a switching valve loaded a portion of the eluting compound onto a protein-bonded chiral stationary phase which resolved 2 into the (+) and (-) stereoisomers using an aqueous mobile phase of potassium phosphate (pH = 6.25) and 5% 2-propanol. All eluting compounds were monitored using UV detection at 214 nm, and no plasma endogenous material or other commonly used psychotropic drugs were found to interfere. Within-day and between-day variation were less than 6% over the expected concentration range, and a limit of quantitation of about 125 ng/mL of 2 was observed. Steady-state plasma samples from 17 patients receiving 1 were found to contain the (-) enantiomer to the extent of about 96% of total 2. The potential clinical implications of these results are not known since all previous pharmacological studies were carried out with the racemic 2.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9192113     DOI: 10.1002/(SICI)1099-0801(199705)11:3<174::AID-BMC681>3.0.CO;2-E

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  9 in total

Review 1.  Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent.

Authors:  Linda P Dwoskin; Anthony S Rauhut; Kelley A King-Pospisil; Michael T Bardo
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

Review 2.  Central nervous system biogenic amine targets for control of appetite and energy expenditure.

Authors:  David L Nelson; Donald R Gehlert
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

3.  Development and validation of a high-throughput stereoselective LC-MS/MS assay for bupropion, hydroxybupropion, erythrohydrobupropion, and threohydrobupropion in human plasma.

Authors:  Aaron M Teitelbaum; Alicia M Flaker; Evan D Kharasch
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-02-27       Impact factor: 3.205

4.  Transdermal delivery of bupropion and its active metabolite, hydroxybupropion: a prodrug strategy as an alternative approach.

Authors:  Paul K Kiptoo; Kalpana S Paudel; Dana C Hammell; Raghotham Reddy Pinninti; Jianhong Chen; Peter A Crooks; Audra L Stinchcomb
Journal:  J Pharm Sci       Date:  2009-02       Impact factor: 3.534

5.  Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes.

Authors:  Rebecka Coles; Evan D Kharasch
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

6.  Stereoselective method to quantify bupropion and its three major metabolites, hydroxybupropion, erythro-dihydrobupropion, and threo-dihydrobupropion using HPLC-MS/MS.

Authors:  Andrea R Masters; Michael McCoy; David R Jones; Zeruesenay Desta
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-02-18       Impact factor: 3.205

7.  Stereoselective Glucuronidation of Bupropion Metabolites In Vitro and In Vivo.

Authors:  Brandon T Gufford; Jessica Bo Li Lu; Ingrid F Metzger; David R Jones; Zeruesenay Desta
Journal:  Drug Metab Dispos       Date:  2016-01-22       Impact factor: 3.922

8.  Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers.

Authors:  Andrea R Masters; Brandon T Gufford; Jessica Bo Li Lu; Ingrid F Metzger; David R Jones; Zeruesenay Desta
Journal:  J Pharmacol Exp Ther       Date:  2016-06-02       Impact factor: 4.030

9.  Stereoselective Bupropion Hydroxylation by Cytochrome P450 CYP2B6 and Cytochrome P450 Oxidoreductase Genetic Variants.

Authors:  Pan-Fen Wang; Alicia Neiner; Evan D Kharasch
Journal:  Drug Metab Dispos       Date:  2020-04-01       Impact factor: 3.922

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.